^
    1d
    AcceleRET Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).
    Trial termination
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    1d
    A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • paclitaxel • pemetrexed • Aidixi (disitamab vedotin)
    2d
    HARMONi-A: Phase 3 Clinical Study of AK112 for NSCLC Patients (clinicaltrials.gov)
    P3, N=322, Active, not recruiting, Akeso | Trial completion date: Nov 2025 --> Sep 2026
    Trial completion date
    |
    EGFR mutation
    |
    carboplatin • pemetrexed • Yidafan (ivonescimab)
    2d
    J5Q-OX-JRDA: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G12 • KRAS G12S • KRAS G13
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    2d
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
    P2, N=43, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | N=24 --> 43
    Enrollment open • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • calderasib (MK-1084)
    2d
    A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=20 --> 10
    Enrollment closed • Enrollment change
    |
    MTAP (Methylthioadenosine Phosphorylase) • IL17A (Interleukin 17A)
    |
    pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)
    3d
    Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with BRAF V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to BRAF/MEK inhibition. (PubMed, Front Oncol)
    The patient was later hospitalized for "recurrent hemoptysis" and received pemetrexed adjuvant chemotherapy combined with cisplatin...Consequently, a targeted therapy regimen combining low to moderate doses of dabrafenib and trametinib was initiated...Moreover, only one low-grade immune-related adverse event was observed during the course of immunotherapy. Patients with advanced NSCLC and BRAF mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF V600E • PD-L1 overexpression • BRAF V600
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • cisplatin • Tafinlar (dabrafenib) • pemetrexed
    3d
    Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis (PubMed, Zhongguo Fei Ai Za Zhi)
    High-dose Furmonertinib combined with IP is an effective and well-tolerated regimen for EGFR-mutant NSCLC-LM. The addition of Bevacizumab may further improve outcomes, offering a promising strategy for refractory patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Avastin (bevacizumab) • pemetrexed • Ivesa (firmonertinib)
    3d
    Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas (clinicaltrials.gov)
    P2, N=15, Recruiting, Baptist Health South Florida | Trial completion date: Feb 2031 --> Feb 2033 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    pemetrexed • Brukinsa (zanubrutinib)
    3d
    HARMONi: Phase III Study of AK112 for NSCLC Patients (clinicaltrials.gov)
    P3, N=420, Active, not recruiting, Summit Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    carboplatin • pemetrexed • Yidafan (ivonescimab)
    4d
    AK112-201: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2, N=265, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • pemetrexed • Yidafan (ivonescimab)
    4d
    3082-CL-0101: A Study of ASP3082 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=681, Recruiting, Astellas Pharma Inc | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • leucovorin calcium • setidegrasib (ASP3082)